MYMD MyMD Pharmaceuticals
- 2.500
- -0.030-1.19%
MyMD Pharmaceuticals News
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ:TLRY) fell sharply during Tuesday's session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free cash flow for the full fiscal year 2024.
Molecular Templates, Acorda Therapeutics, MyMD Pharmaceuticals Among Healthcare Movers
MyMD Pharmaceuticals Filing From Late Monday Shows Co. Entered Omnibus Waiver And Amendment Agreement With Required Holders Under Previously Announced Securities Purchase Agreement
As previously disclosed, on February 21, 2023, MyMD Pharmaceuticals, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with certain accredited investors (the
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data
US stocks were set to open slightly higher in Tuesday's trading session as investors looked ahead to March inflation data and the FOMC March meeting minutes slated for release on Wednesday. The Dow Jo
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell
US stock futures were flat in Tuesday's premarket session ahead of a relatively subdued day on the economic calendar as investors looked ahead to inflation data and the Federal Reserve's March meeting
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersAcrivon Therapeutics (NASDAQ:ACRV) stock moved upwards by 72.3% to $10.19 during Tuesday's pre-market session. The market value of their outstanding shares is at $230.5 million. Biophytis (NASD
Top Premarket Gainers
Acrivon Therapeutics (ACRV) shares surged 72% in recent premarket activity Tuesday after it said it signed a securities purchase agreement with select current and new accredited investors to issue and
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Shares of Biophytis S.A. (NASDAQ:BPTS) rose sharply in today's pre-market trading after reporting FY23 results. Biophytis posted a FY23 loss of €0.03 per share, versus a year-ago loss of €0.14 per s
MyMD Pharmaceuticals Enhances Governance and Financing Structure
MyMD Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement for Continued Listing
Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
MyMD Pharmaceuticals To Carry Out 1-for-30 Reverse Stock Split On February 15th, 2024
February 14th - $MyMD Pharmaceuticals(MYMD.US)$ is about to implement a 1-for-30 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from February 15th, 2024.$MyMD P
MyMD Pharmaceuticals to Implement 1-for-30 Reverse Stock Split
MyMD Pharmaceuticals (MYMD) said Tuesday it intends to implement a reverse stock split at a 1-for-30 ratio to maintain its listing on Nasdaq. The reverse split will be effective at 4:05 pm ET on Wedne
MyMD Pharmaceuticals Announces Reverse Stock Split To Maintain Nasdaq Listing >MYMD
MyMD Pharmaceuticals Announces Reverse Stock Split To Maintain Nasdaq Listing >MYMD
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersTivic Health Systems (NASDAQ:TIVC) stock rose 25.9% to $1.75 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.5 million. Bullfrog AI Hldgs (NASDAQ:BF
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersMoleculin Biotech (NASDAQ:MBRX) shares moved upwards by 8.7% to $0.72 during Tuesday's after-market session. The market value of their outstanding shares is at $23.9 million. Evoke Pharma (NASD
MyMD Pharmaceuticals Has Been Granted Canadian Patent Number 3013634 Titled "Methods Of Increasing Hair Growth And Improving Hair Appearance"
MyMD Pharmaceuticals Has Been Granted Canadian Patent Number 3013634 Titled "Methods Of Increasing Hair Growth And Improving Hair Appearance"
MyMD Says 'In a Recently Completed Phase 2 Clinical Trial, MYMD-1 Met Both of Its Primary Endpoints'
MyMD Says 'In a Recently Completed Phase 2 Clinical Trial, MYMD-1 Met Both of Its Primary Endpoints'
MyMD Pharmaceuticals Highlights Results For Sarcopenia Treatment Drug
MyMD Pharmaceuticals Highlights Results For Sarcopenia Treatment Drug
Analysis
Price Target
No Data
